Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells

Jian Song1, Xiaobo Wang, Jiaxue Zhu

  • 1Department of Orthopaedics, Shandong Jining No.1 People's Hospital, Jining, Shandong, 272000, China.

Abstract

Insights

Rapamycin effectively inhibits chondrosarcoma cell growth and invasion. This mTOR inhibitor shows promise as a targeted therapy for chondrosarcoma, reducing tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chondrosarcoma is a malignant bone tumor resistant to conventional treatments.
  • Rapamycin (mTOR inhibitor) has diverse cellular effects but its role in chondrosarcoma is unclear.

Purpose of the Study:

  • To investigate the effects of rapamycin on human chondrosarcoma cell proliferation, cell cycle, and invasion.
  • To evaluate rapamycin's efficacy in a preclinical chondrosarcoma xenograph model.

Main Methods:

  • MTS assays, flow cytometry, and invasion assays were used on SW1353 and JJ012 cell lines.
  • Quantitative RT-PCR analyzed gene expression related to cell cycle and invasion.
  • Mice xenograft models assessed in vivo tumor growth inhibition.

Main Results:

  • Rapamycin significantly reduced chondrosarcoma cell proliferation and invasion.
  • Cell cycle arrest was induced by rapamycin.
  • Rapamycin treatment led to significant inhibition of tumor growth in vivo.

Conclusions:

  • Rapamycin demonstrates potent anti-cancer effects against human chondrosarcoma cells.
  • Targeted therapy with rapamycin presents a potential therapeutic strategy for chondrosarcoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K